Skip to main content

Home/ Pharmaceutical Laboratory/ Group items tagged moody

Rss Feed Group items tagged

Filter: All | Bookmarks | Topics Simple Middle
hamelinclara

Myiris news - News - Stable outlook for global pharma industry in 2013: Moody's - 0 views

www.myiris.com/...storyShow.php

moody outlook

shared by hamelinclara on 23 Apr 13 - No Cached
  • hamelinclara on 23 Apr 13
     
    "Stable outlook for global pharma industry in 2013: Moody's "
hamelinclara

Success at The End of The Patent Cliff: How High Performing Pharma Companies Are Prepar... - 1 views

social.eyeforpharma.com/...pharma-patent-cliff-new-normal

patent success pharma stratégies

shared by hamelinclara on 22 Jan 13 - No Cached
  • Anne O’Riordan, Global Industry Managing Director of Accenture’s Life Sciences group, believes that this offers an engine for return to growth.Moody’s Credit Outlook agree and in response they have upgraded their outlook for the Pharmaceutical Sector from Negative to Stable, pointing out that “the multiyear wave of drug patent expirations that have squeezed profits should subside next year”.
  • Global pharmaceutical company GlaxoSmithKline has been hugely successful at supporting a culture of innovation with smaller entrepreneurial units as well as developing strengths in the consumer health markets in the Middle East and Asia.
  • Bristol-Meyers Squibb has also developed a very specific strategy and targeted unmet clinical needs, such as biological dugs and oncology, as well as executed some creative deals with big pharma companies and implemented fundamental internal organisational changes.
  • ...5 more annotations...
  • Novartis, in the face of the loss of patent protection on its top selling pharmaceutical, has managed to weather the patent cliff storm because of two key factors: the development of innovative drugs and its diversity in holding other business interests, with over-the-counter and vaccine business delivering a major portion of their growth this year.
  • positive about what is happening in the pharma sector and believe there is a growing portion of non-patent cliff expose revenues within this group: “We are increasingly seeing investor interest in the pharma group shifting to longer-term growth prospects/pipeline expectations as the sector moves beyond its 2012/2013 patent cycle”.
  • Roche has been doing some of their own research and see no major threat from patent expiration. They are comforted by the fact that US patents for some of their most successful oncology drugs are safe until 2016 and that the full market development of competitive drugs is unlikely to really kick in until 2015 due to factors such as complicated approval processes. In addition, this company is spending around 50 percent of total R&D on its oncology pipeline, which they believe will deliver significant returns.
  • Success requires the commitment and discipline to have a clear strategy and be decisive about where a company can focus and remain visible. In addition, it is critical to build new capabilities so emerging markets are readily identified, expedient product launches are delivered, R&D is undertaken collaboratively and multichannel marketing is put into practice.
  • ere are companies exhibiting a discipline for change and investors are rewarding them for that. So don’t lose sight of fact that there are plenty of opportunities for growth going forward”
1 - 2 of 2
Showing 20▼ items per page